Today's digest has 27 items: seven each from medchem, computational and industry, six from pharmacology. Highlights: Sanofi dropping Nurix's STAT6 degrader, Boehringer's up-to-$7B Sino Biopharm options, and a reality check on diffusion-guided MD sampling.
2026-11-04 · ⚗️HCoV-OC43 M-N structural protein interaction (small-molecule aminopyrimidines) · Journal of Medicinal Chemistry
- An aminopyrimidine series built from a pyrimidine lead was profiled for anti-HCoV-OC43 activity in cells.
- Top compound 13h paired strong potency with a wide selectivity window and a good safety profile.
- It appears to bind residue V201 of the membrane protein M at the M-N interface, disrupting the association needed for virion assembly.
- First small molecule aimed at this interface, with a mechanism unlike existing coronavirus drugs.
💡 PointsBased on the abstractMost coronavirus antivirals hit the protease or polymerase, where resistance routes are well mapped; a virion-assembly interface is a genuinely different bet. The next step is a V201 mutant that loses both binding and antiviral effect, plus SPR or a thermal shift on M, and a check that 13h doesn't simply act on a host kinase.
Discovery and Identification of a Novel Class of Aminopyrimidine Derivatives Specifically Blocking the Interaction between the M and N Structural Proteins of the Coronavirus HCoV-OC43 ↗
2026-11-04 · ⚗️Dual HDAC / PD-1/PD-L1 small-molecule inhibitors · Journal of Medicinal Chemistry
- Six hybrids combine histone deacetylase inhibition with PD-1/PD-L1 blockade in one molecule.
- Two leads differ in isoform preference, HDAC6-selective versus HDAC1-3; both disrupt the checkpoint pair and lower tumor cell viability in vitro.
- The HDAC6 lead eased T cell exhaustion, boosted neutrophil and NK activity in vivo, and worked in BRAF-mutant melanoma, including vemurafenib-resistant cells.
- The HDAC1-3 lead was cytotoxic but raised PD-L1 expression, so isoform choice matters.
💡 PointsBased on the abstractSet against dosing an HDAC inhibitor alongside a checkpoint antibody, one hybrid sidesteps PK mismatch but pays in size and lipophilicity, with a hydroxamate warhead on a biphenyl-type PD-L1 binder. PD-1/PD-L1 disruption needs confirming by HTRF and a cellular assay. The PD-L1 rise from the HDAC1-3 lead is a useful warning; HDAC6 looks the series to push.
Dual Histone Deacetylase/PD-1/PD-L1 Inhibitors Reprogram Tumor−Immune Interactions and Are Effective in Therapy-Resistant Melanoma ↗
2026-11-04 · ⚗️pre-miR-21 / lysosomal RNA-degrading chimera (LyRAC) · Journal of Medicinal Chemistry
- Structure-guided screening of full-length pre-miR-21 picked the kinase inhibitor dovitinib as an RNA binder; binding studies mapped its contacts and modifiable sites.
- Linking it to the LC3B ligand GW5074 gave DPG-3, which bridges RNA and LC3B and routes the RNA to autophagy-lysosome clearance.
- In liver cancer cells DPG-3 beat a dovitinib RiboTAC at lowering pre-miR-21 and miR-21-5p and at curbing proliferation.
💡 PointsBased on the abstractRiboTACs recruit RNase L; this chimera uses the autophagy-lysosome route instead, widening the toolbox for structured RNAs. The convincing next experiment pairs dovitinib-only and GW5074-only controls with lysosome-inhibitor rescue, plus a kinase counter-screen, since dovitinib is a promiscuous ATP-site binder and selectivity over other structured RNAs is untested.
Lysosomal Degradation of MicroRNA-21 Precursor by a Small-Molecule Chimera ↗
2026-11-03 · ⚗️Fragment screening (methodology) · ChemMedChem
- A single-author perspective on two basic FBDD design choices: the screening method and the size of the fragment library.
- The author lays out the method and library size used in their own lab, with reasons for each.
- A worked example illustrates the benefits, offered as one viewpoint since practice varies widely.
💡 PointsBased on the abstractLibrary size means little without hit rate and ligandability data: a few hundred well-curated fragments that give clean, soluble, orthogonally confirmed binders can beat thousands run through one noisy readout. For anyone choosing a setup, the numbers to ask for are how many hits were crystallographically validated and their ligand efficiencies, since those decide whether a fragment can be grown.
What Method and Library Size Is Best for Fragment Screening? ↗
2026-11-03 · ⚗️PD-L1 (small-molecule immune checkpoint inhibitor) · ACS Medicinal Chemistry Letters
- N-acyl pyrimidine-biphenyl compounds were made as non-antibody PD-L1 blockers, since no small-molecule drug against this checkpoint is approved.
- Reporter-cell screening flagged two hits; dynamics modeling tied the better one, A6, to stable contact with D122.
- A6 weakened PD-1/PD-L1 binding in ELISA, far less potently than in cells.
- In cells it revived T cell activity and tumor killing; in syngeneic 4T1 mice it slowed tumor growth without visible systemic toxicity.
💡 PointsBased on the abstractCell potency outrunning ELISA potency is the pattern to watch. BMS-type biphenyl PD-L1 binders act by inducing PD-L1 dimerization, and cell readouts can hide cytotoxicity, so SPR/HTRF binding, a dimerization assay and an inactive analog should come before any D122 contact optimization. The next gate is whether 4T1 efficacy holds in human PD-L1 models.
Discovery of N -Acyl Pyrimidine-Biphenyl Small-Molecule PD-L1 Inhibitors that Restore T Cell Function and Suppress Tumor Growth in Breast Cancer ↗
2026-11-02 · ⚗️TERRA RNA G-quadruplex; indoloquinoxaline small-molecule ligand · Angewandte Chemie International Edition
- An indoloquinoxaline scaffold was developed to bind the RNA G-quadruplex of TERRA, a long non-coding RNA important in telomerase-independent (ALT) cancers.
- Biophysics showed tight, selective recognition; NMR and modeling point to stacking on the terminal G-tetrad.
- The ligand weakens TERRA-TRF2 association and shifts TERRA levels and ALT-related gene expression.
- In ALT-positive U2OS cells it reaches the nucleus, causing telomere-linked DNA damage, S-phase arrest and apoptosis.
💡 PointsBased on the abstractFlat polyaromatics stacking on a terminal G-tetrad is the classic G4 recipe, so selectivity over DNA quadruplexes and the many other RNA G4s is the open question. U2OS DNA damage could also come from binding telomeric DNA G4. A TERRA-mutant or G-to-U control and a TRF2-knockdown rescue would tie the phenotype to TERRA.
Small Molecule Modulation of TERRA RNA Quadruplex Reprograms ALT‐Telomere Maintenance ↗
2026-10-30 · ⚗️Molecular glue degraders; TEM β-lactamases recruited to periplasmic protease DegP · Angewandte Chemie International Edition
- Small molecules were found that bring TEM-type β-lactamases to the periplasmic protease DegP, so the resistance enzyme is destroyed rather than merely blocked.
- Tazobactam itself sped DegP-mediated turnover; adding linker-free dipeptide motifs common in DegP substrates boosted it further.
- With piperacillin, the optimized glues outperformed tazobactam against resistant E. coli and showed oral-compatible pharmacokinetics.
💡 PointsBased on the abstractResistance enzymes are usually inhibited, which selects for escape variants; degradation only changes that if the glue also works on free enzyme, not just acylated TEM, given tazobactam's covalent mechanism. Linker-free dipeptides hint the enzyme is read as an ordinary DegP substrate. Activity against KPC and CTX-M would show how general the strategy is.
Molecular Glue Degraders of TEM β‐Lactamases by Periplasmic Protease DegP ↗
2026-11-04 · 🧬Metformin (repurposed antidiabetic) in a rat cocaine-sensitization model · Journal of Pharmacology and Experimental Therapeutics (ASPET)
- Metformin, an antidiabetic drug being repurposed for addiction, was given to rats in drinking water for one to several weeks, and its levels were then measured by mass spectrometry in blood and in striatal and prefrontal tissue.
- Brain levels were comparable across the sampled regions in both sexes. Rats cut their water intake as concentration rose, so a stronger solution did not necessarily mean higher plasma or brain levels.
- Free access to metformin water prevented cocaine locomotor sensitization in males only, which the authors take to suggest a sex difference in how the drug distributes across the blood–brain barrier.
💡 PointsBased on the abstractNice to see actual brain levels, since most repurposing work just assumes metformin gets in. But drinking-water dosing is a messy way to define exposure: intake falls at higher doses, and rats drink nocturnally, so peak and trough are uncontrolled. Tissue totals also don't give free, intracellular or mitochondrial concentrations, which is where AMPK or complex I effects would happen. Next: gavage or osmotic pump with a dose-response in both sexes.
Metformin pharmacokinetics in the rat brain: dose- and time-dependent concentrations in reward-relevant regions and differential effects on cocaine locomotor sensitization ↗
2026-11-04 · 🧬Synthetic homogeneous heparin oligosaccharide (LMWH alternative) · Science Translational Medicine (AAAS)2026, 18 (874), eaeg0408
- A uniform, chemoenzymatically built heparin oligosaccharide carries extra sulfation that stiffens its shape and weakens platelet factor 4 binding, while the antithrombin-binding region stays intact.
- In mice, antithrombotic efficacy matched enoxaparin in venous settings and exceeded it in arterial ones, and protamine reversed the compound more readily.
- HIT-mimicking antibodies barely activated human platelets, and liver toxicity and immunogenicity were low.
💡 PointsBased on the abstractMouse PF4 biology is a weak stand-in here: HIT hinges on human PF4/heparin complexes and FcγRIIa-driven platelet activation, so I would not lean on the mouse efficacy. Beating enoxaparin in arterial models is notable, but I want anti-Xa and aPTT exposure matching and bleeding time at equipotent doses. Next: ex vivo HIT sera from real patients, plus primate PK and half-life.
A synthetic heparin oligosaccharide decouples anticoagulation from heparin-induced thrombocytopenia risk ↗
2026-11-03 · 🧬PTP4A3 (PRL-3) phosphatase; small-molecule inhibitor JMS-053 · ACS Pharmacology & Translational Science (ACS)
- Public leukemia datasets link high PTP4A3 expression to poorer patient outcomes, unstable genomes and heightened oncogenic signaling in acute myeloid leukemia.
- Blocking the phosphatase with the inhibitor JMS-053 in leukemia cell lines curbed viability and colony formation, triggered apoptosis, and gradually dampened ERK1/2 phosphorylation.
- Combining JMS-053 with cytarabine produced synergistic effects, supporting PTP4A3 as both a risk marker and a candidate target; findings are preclinical.
💡 PointsBased on the abstractPhosphatases have a poor druggability record, and JMS-053 is a tool compound, not a drug. It is a thienopyridone-type inhibitor with a history of redox and selectivity worries across the PTP family. Before I'd believe the ERK1/2 story or the cytarabine synergy, I'd want a PTP4A3 knockdown or catalytic-dead rescue to rule out off-target effects. Next: patient-derived blasts, plus an in vivo xenograft with measured exposure.
Protein Tyrosine Phosphatase 4A3 (PTP4A3) as a Prognostic Biomarker and Pharmacological Target in Acute Myeloid Leukemia ↗
2026-11-03 · 🧬K2P channels TREK-1 (K2P2.1) / TASK-4 (K2P17.1) heteromers · British Journal of Pharmacology (Wiley)
- TREK-1 and TASK-4, potassium channels from separate K2P subfamilies that are found together in heart and pancreatic beta cells, can assemble into mixed channels.
- Using oocyte voltage-clamp, excised-patch recordings and imaging/surface-expression assays, the hybrids showed altered pH, temperature and sodium sensitivity.
- Unlike TREK-1, the hybrids escape inhibition through Gs-coupled signalling and respond differently to drugs, suggesting new angles for arrhythmia and diabetes therapy.
💡 PointsBased on the abstractOocyte expression is a forgiving system: you force a 1:1 co-injection, then ask whether heteromers form. Missing is any sign they exist natively in cardiomyocytes or beta cells, which needs co-IP or proximity ligation from primary tissue, plus a heteromer-selective blocker or knockout to prove function. Without that, the drug-response differences are a screening curiosity, not a target. Next step: native currents in isolated cells.
Crossing subfamily borders: Mechanosensitive TREK‐1 and alkaline‐activated TASK‐4 form heterodimers with unique functional and pharmacological properties ↗
2026-10-10 · 🧬Bifunctional peptide (exendin-4/apelin) agonist of GLP-1R and apelin receptor · Biochemical Pharmacology (Elsevier)2026, 254 (Pt 3), 118534
- A single bifunctional peptide, ELA, fuses an exendin-4 GLP-1 agonist element with apelin to engage both receptor systems.
- In MPTP-lesioned mice, benchmarked against liraglutide, it improved movement and dampened neuroinflammation.
- It also preserved striatal synapses and restored mitochondrial fission/fusion balance, beating liraglutide on some readouts but not all.
💡 PointsBased on the abstractBeating liraglutide only on some readouts in one MPTP model is a thin basis for calling dual agonism better, since acute MPTP recovers spontaneously and barely mimics progressive alpha-synuclein pathology. Without brain exposure, a dose-response, and a mixed GLP-1 plus apelin co-dosing arm, you can't tell synergy from simply higher potency. Next: pharmacokinetics, then a chronic or alpha-syn model.
A GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's disease ↗
2026-10-08 · 🧬Bruton tyrosine kinase (BTK); oral covalent small-molecule inhibitor · Drug Metabolism and Disposition (ASPET)2026, 54 (11), 100417
- A radiolabelled oral dose plus intravenous microdoses in healthy volunteers mapped how the covalent BTK inhibitor remibrutinib is absorbed, distributed and cleared at steady state.
- The drug was taken up quickly, spread widely into tissues and was extensively metabolised, with most elimination through the feces.
- Radioactivity recovery was incomplete after oral dosing but nearly complete after the intravenous microdose, which helps separate absorption from clearance.
- No circulating metabolite made up a major share of drug-related material, and the drug was well tolerated.
💡 PointsBased on the abstractIncomplete recovery after the oral dose but near-complete after the IV microdose suggests the loss sits in the absorption phase rather than in a tissue sink, and the microdose is what lets you separate that from clearance. For a covalent inhibitor, also ask how much label stays irreversibly on protein. Extensive metabolism with fecal dominance makes a hepatic-enzyme DDI study the sensible next step.
Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state ↗
2026-11-05 · 💻Review / diffusion-based generative molecular design · chemRxiv
- A PRISMA-ScR scoping review of diffusion-based networks for de novo drug design published between 2020 and 2026.
- Diffusion did not replace earlier architectures; graph networks, autoencoders and transformers remain the backbones, with the training objective being what changed.
- Conditioning approaches fall into structural anchoring, target-aware biochemical conditioning, property-driven steering and multimodal latent conditioning; when the signal enters the reverse trajectory is itself a design choice.
- Datasets, metrics and definitions differ across papers, leaving gaps in controllability and interpretability.
💡 PointsBased on the abstractThe useful claim is the third finding: with no common benchmark or metric definitions, papers cannot be ranked, so the headline validity and novelty numbers in generative papers should be read as self-reported. When you pick a generator for a project, ignore the leaderboard and test two or three on your own target with the same docking and synthesizability filters. Reviews like this are most valuable as a map of which conditioning approach fits which input you have.
A Scoping Review of Diffusion-Based De Novo Molecular Generation: Architectures, Evaluation, and Open Challenges for Computational Drug Discovery ↗
2026-11-05 · 💻ML benchmark audit / chiral chromatography enantioselectivity · chemRxiv
- The authors curated the largest public chiral chromatography dataset into over ten thousand enantiomer pairs across hundreds of source papers and many columns.
- Under a random split, elution-order prediction looked clearly better than chance; under leave-one-paper-out it fell to the level of a within-paper permutation null.
- Much of the variance is between papers and is not predictable from the recorded conditions, and most of the remainder is an unidentifiable molecule-by-condition interaction plus noise.
- They argue the bottleneck is data structure and call for condition metadata, systematic grids, replicates and recorded failures.
💡 PointsBased on the abstractThis is the same lesson as the ADMET and peptide leakage audits earlier this week, now in analytical chemistry: group-aware splits by source, not molecule, are what show whether a model transfers to the next lab. If your team ranks chiral methods or predicts retention from literature data, expect nothing beyond a prior. The data-collection checklist at the end is the actionable part.
Where machine learning for enantioselectivity on polysaccharide chiral stationary phases actually fails: a leave-one-paper-out reappraisal of 10,525 enantiomer pairs ↗
2026-11-05 · 💻Protein language model / annotation and variant effect prediction · bioRxiv
- PALM jointly predicts domain and functional-site occurrence from sequence, keeping overlapping and nested annotations through a soft-target objective; it builds on ESM2 with low-rank adaptation and a recurrent encoder.
- It was trained on roughly 15 million InterPro-annotated sequences and kept good performance on proteins with low identity to the training data, beating an ESM3 annotation baseline.
- Without any pathogenicity labels, disruption of its embeddings separated ClinVar missense variants better than ESM2 alone, and a combined score outperformed AlphaMissense on a literature-derived set absent from ClinVar.
💡 PointsBased on the abstractVariant effect predictors tend to look strongest on ClinVar because the labels and the training signals overlap, so the literature-derived set outside ClinVar is the number to watch. For a target team, the site-level annotation is the immediately usable part: it can flag whether a missense found in a patient cohort falls in a binding or catalytic site. Whether it handles variants in intrinsically disordered regions is not addressed in the abstract.
A protein language model for domain, functional site, and variant effect prediction ↗
2026-11-04 · 💻Pocket-conditioned generative design / MDM2–p53 macrocyclic peptides · chemRxiv
- Two rounds of DNA-encoded library selection on symmetric then asymmetric macrocyclic peptides pointed to an enriched half-scaffold, which was kept fixed.
- The selection signals, generated conformations and MDM2 pocket poses trained a pocket-conditioned SE(3)-equivariant flow-matching model that varies side chains around the macrocyclic core.
- From two templates, 40 candidates were generated; two were prioritized and resynthesized off DNA, and both inhibited MDM2–p53 in fluorescence polarization, in the micromolar IC50 range.
- The authors conclude that DEL signals plus pocket geometry can guide generation of macrocycles not present in the library.
💡 PointsBased on the abstractUsing DEL enrichment as the training prior rather than scarce IC50 data is the clever part, and it answers the usual data-scarcity problem for macrocycles. But micromolar hits from 2 of 40 candidates is a modest return when the DEL itself already produced enriched binders; the question is how it compares with simply picking more library members. Check selectivity against MDM4 and the cell activity next.
DEL-Flow: AI-Driven Structural Generation and Activity Validation of MDM2-Targeting Macrocyclic Peptides ↗
2026-11-04 · 💻Adaptive MD sampling / generative restart selection · chemRxiv
- On adenylate kinase, the authors first audited a workflow that rebuilds restart structures from a diffusion model's latent space; by native-contact checks most were damaged from the first frame.
- They then compared diffusion-based restart selection with a latent Gaussian ablation, least-counts and unbiased baselines, using intact MD frames, pre-specified targets, equal simulation time and three replicates.
- No strategy reached the primary target within the budget; adaptive restarts covered the reference distribution slightly better than baselines, but the diffusion model got no closer to the target than the simple strategies.
- Choosing starts by latent-space novelty tended to select frames farther from the target than random picks.
💡 PointsBased on the abstractI like that the targets were fixed and timestamped before production runs; that is how an ML-for-MD claim should be tested, and it is rare. The practical message for anyone running enhanced sampling on a drug target is to try least-counts first and to check that a generative model's structures are physically intact before spending GPU time on them. One small protein limits how far this generalizes.
Diffusion-Model-Based Restart Selection for Adaptive Sampling of Adenylate Kinase: Structural Integrity Assessment and Comparison with Simple Baselines ↗
2026-11-04 · 💻Protein–protein interaction prediction / calibration · bioRxiv
- PPI-Caliper is a model-agnostic wrapper that applies conformal calibration to pick protein interactions at a user-set false discovery rate, using held-out labels and no retraining.
- Across five species and two protein-language-model predictors, each with two versions of human training data, the empirical error rate stayed at or below target when calibration data matched the test data.
- Under distribution shift, thresholds carried over from another setting turned conservative when predictions improved but could fail to control errors when performance dropped.
💡 PointsBased on the abstractFor target discovery the benchmark AUC was never the real question; it is how many of the top-ranked interactions you can afford to chase before the follow-up assays dry up. An explicit FDR dial answers that, and the honest shift result matters most: calibrating on a well-studied organism then applying to a poorly annotated one is exactly where it can break. Try it on an in-house interactome with orthogonal validation before trusting it.
Error-Controlled Discovery of Protein Interactions via Conformal Calibration ↗
2026-11-03 · 💻Machine-learned force field scoring / protein–ligand binding energy · chemRxiv
- SO3LR-SF combines pretrained SO3LR machine-learned force fields with physics-based terms for repulsion, electrostatics and dispersion to score active-site models of protein–ligand complexes.
- It was tested against high-level quantum references on small active-site models and on two ligand-ranking sets of the kind used for free-energy benchmarks.
- Ranking quality was comparable to the best semi-empirical method and MM/GBSA, above Glide, and in the range of MD-based free-energy methods on one set, at a few seconds to under a minute per complex on CPUs.
- The authors frame it as less exposed to inflated results from training on protein–ligand complexes.
💡 PointsBased on the abstractMatching MM/GBSA and edging Glide is useful, but the FEP sets here are retrospective congeneric series, which are the easy case for any scoring function. I would run it on our own series with known SAR cliffs and see whether it ranks the ones FEP+ gets wrong. If it holds up, 3 to 47 seconds per complex makes it a realistic rescoring layer after docking.
Explainable ML force-field for evaluating protein–ligand binding energy using SO3LR ↗
2026-11-05 · 🏢financing · BioPharma Dive · Alethio Therapeutics
- Alethio Therapeutics, an Oxford spinout founded by Adam Mead and Beth Psaila, raised a $90 million Series A co-led by Sofinnova Partners and RA Capital.
- Lead asset ATX-011 is a preclinical monoclonal antibody against G6b, a receptor on platelets and some marrow cells, intended to work regardless of the driver mutation; clinic entry is guided for the first half of 2028.
- A second candidate, an ADC for myelofibrosis, is also in development.
💡 PointsBased on public reportsA $90 million round for an asset that won't dose a patient until 2028 is a bet on the mutation-agnostic idea: today's therapies mostly target JAK2-driven biology or the mutant clones, and calreticulin-directed antibodies are the obvious comparison. The thing to watch is whether a platelet-lineage receptor can be hit without thrombocytopenia or bleeding. Essential thrombocythemia is a large, long-lived population, which is what makes the commercial case.
Alethio raises $90M to target rare blood cancers ↗
2026-11-04 · 🏢pipeline progress · BioSpace · Amgen
- Amgen has begun another Phase 3 trial of home self-administration of subcutaneous MariTide with an autoinjector; ClinicalTrials.gov lists primary completion in June 2027.
- The MARITIME programme has 10 trials, two more are due to start this year, and the first Phase 3 data are expected in 2027.
- Analysts are focused on tolerability rather than weight loss; R&D chief Jay Bradner said a conventional single-chamber handheld device is planned.
💡 PointsBased on public reportsAmgen's pitch is dosing as rarely as four times a year, which would separate MariTide from Lilly's and Novo's weekly products, but that only matters if dose escalation is tolerable. The device study is the quiet commercial step: using a conventional autoinjector reduces launch risk if the pivotal data land. Both BMO and Truist describe differentiation as unproven, so the first GI-event data from Phase 3 is the real readout.
Amgen starts MariTide autoinjector study as pivotal readouts approach ↗
2026-11-04 · 🏢licensing · BioSpace · Boehringer Ingelheim / Sino Biopharmaceutical (SBP Group)
- Boehringer Ingelheim and SBP Group signed a second oncology collaboration after their 2024 deal: six preclinical antibody–drug conjugate and T-cell engager programs.
- Boehringer pays $358 million upfront and near-term; SBP is eligible for up to $7 billion in option-exercise and milestone payments plus tiered royalties.
- Five programs come from LaNova, one from Beijing Tide. SBP runs early development, and Boehringer can opt in per asset after undisclosed clinical milestones; four options give rights excluding some Asian countries, two give global rights.
💡 PointsBased on public reportsThe structure is the story: Boehringer pays to watch SBP fund the risky preclinical-to-clinic step, then chooses asset by asset, so most of the $7 billion is only paid if programs survive. It is the same China-sourcing playbook Pfizer, Merck and others use, with a Shanghai R&D site added a month ago to evaluate assets in-house. Six ADC/TCE shots in one deal also bets that Chinese bispecific and conjugate engineering stays ahead of Western platforms.
Boehringer bets big on China, offering $7B biobucks for Sino cancer programs ↗
2026-11-04 · 🏢M&A / restructuring · BioPharma Dive · CVS Health
- CVS Health will separate into two public companies, with shareholders owning both; completion is expected in the first half of 2028.
- The new CVS Health keeps Aetna, the Caremark PBM, Oak Street, Signify and specialty pharmacy; CVS Pharmacy takes roughly 9,000 stores, mail order and walk-in clinics.
- CEO David Joyner said the move is not driven by regulatory pressure and that Aetna–Caremark ties will continue under commercial agreements; it came with a raised 2026 outlook.
💡 PointsBased on public reportsFor drugmakers the interesting part is Caremark staying with the insurer: the PBM rebate and formulary leverage is intact, while a standalone pharmacy becomes a cleaner counterparty for dispensing and margin negotiations. Analysts also see the split easing state scrutiny of vertical integration, so expect policymakers to ask whether commercial agreements between the halves recreate the same incentives. Timeline to 2028 leaves room for this to change.
CVS to split into two companies in stunning strategic about-face ↗
2026-11-04 · 🏢discontinuation · BioPharma Dive · Sanofi / Nurix Therapeutics
- Sanofi has discontinued SAR448272, the oral STAT6 degrader it licensed from Nurix; Sanofi pointed to new nonclinical findings in eczema models and said it still values the STAT6 pathway.
- The 2020 collaboration carried $55 million upfront and up to $2.5 billion in potential payments; Sanofi exercised its option last year and paid a $10 million milestone when Phase 1 began in August.
- Nurix shares fell more than 40%, though analysts said its lead asset, bexobrutideg (partnered with Roche), is unaffected.
💡 PointsBased on public reportsNobody outside the two companies can say what the nonclinical signal was, which is the real problem: a safety or tolerability finding in a degrader would rewrite the read-across, while a molecule-specific flaw would not. Kymera's STAT6 degrader, with a mid-stage readout due, is now the class test, and Sanofi's second STAT6 programme with Recludix shows it is not walking away from the target. Watch whether Nurix retains rights.
Sanofi stops development of Nurix-partnered immune drug ↗
2026-11-03 · 🏢regulatory · BioPharma Dive · uniQure
- The FDA has agreed to review uniQure's application for its Huntington's disease gene therapy on an accelerated timeline, with a decision due May 1.
- The agency also tentatively plans to consult external advisers on the application.
- Shares fell about 7% by late Monday, though analysts mostly read the update as positive; TD Cowen models annual sales reaching $1.6 billion by 2039.
💡 PointsBased on public reportsA first approval in Huntington's would be a landmark for CNS gene therapy, but the open question is the evidence package: a committee meeting signals the agency wants outside views on the data and on how benefit is judged in a slowly progressing disease. The stock dipping on good news suggests investors had priced a faster path. Compare how regulators treated other single-arm gene therapy filings before assuming approval.
UniQure gets an FDA decision date; Teva scraps brain drug study ↗
2026-11-03 · 🏢regulatory · BioPharma Dive · Vertex Pharmaceuticals
- Vertex says it is ready to launch povetacicept in IgA nephropathy; an FDA approval could come by the end of November.
- A late-October citizen petition asks the FDA to require antibody-level monitoring because of infection risk; Vertex did not directly address it on the call.
- Q3 revenue rose 12% to $3.44 billion, with Alyftrek and Casgevy ahead of estimates and Journavx below; full-year guidance was nudged up to $13.15–13.25 billion.
💡 PointsBased on public reportsThe petition matters more than the earnings beat: if the label ends up with immunoglobulin monitoring, a monthly home autoinjector loses some of its convenience edge over the two IgAN drugs already on the market. Vertex is also launching a low-volume, highly concentrated device at scale for the first time outside cystic fibrosis, so supply is a second thing to check. The $10 billion Crinetics purchase is weighing on near-term earnings per share.
Vertex, ahead of FDA decision, calms fears surrounding kidney drug ↗
